Creative Bio-Peptides (CBP) was started in late 2017 with the mission to improve patients lives by challenging prevalent conventions about the causes and treatment approaches of neurodegenerative diseases. We seek to make a positive impact in people’s daily lives by reversing disease causing processes to improve a disabling condition. We strive to bring to market innovative therapeutics for important conditions caused by innate immune system activation in neuropathies, dementias, brain injuries, and substance use disorders.
We have created dozens of orally-active peptides representing over $75M in legacy research and development related to the first generation peptide (non-oral) which has been shown to be safe and effective in multiple controlled trials for improving cognitive endpoints in more severely impaired individuals (1, 2, 3). Our new oral lead compound RAP-103 is near phase 1 ready and is shown to be safe in animal toxicity studies with rapid brain entry and stability.
Our current developmental focus is in chronic neuropathic pain conditions and neuropathies, such as diabetic peripheral neuropathy (DPN). Chronic pain results from persistent innate immune activation that then damages neurons. RAP-103 (R103) blocks chronic pain without need for opioids (4), and enhances opioid potency to relieve pain at lower opioid doses. Blocking chemokine receptor activation also blunts drug-seeking behaviors in animals and R103 is being evaluated for its use in opioid use disorders with funding from NIDA, NIH. [1R43DA050349]
We are also developing our RAP peptides as treatments for cognitive decline in dementias and have been funded by the NIA, NIH [1R43AG071064]. Prior clinical success in reversing cognitive deficits in Neuro-AIDS with the non-oral peptide CCR5 antagonist DAPTA de-risks what has been a challenging therapeutic area and provides a treatment roadmap for many neurodegenerative conditions.
The next steps are to progress the lead peptide into human safety and pilot efficacy testing. We invite you to review the scientific information and clinical results provided throughout this web site, and to contact us if you have an interest to partner with us.
We pursue innovative strategies for pain, dementias, stroke recovery, brain injury and neuro-degenerative conditions. We seek to reverse disease processes and restore normal function. Persistent innate immune inflammation is the root cause for chronic pain and neurodegenerative conditions resulting in loss of synapses and neurons. Instead of treating symptoms, we treat the innate immune system itself to restore synapses and prevent neuronal losses in AD, TBI, PD, and other neurodegenerative conditions. We have a broad pipeline of promising multi-chemokine receptor (CCR2/CCR5/CCR8) targeted oral peptide drug candidates. CCR5 is a validated target to promote neuroregeneration (Science, Feb, 2019).
Neurodegeneration, which also leads to chronic pain, in addition to cognitive decline, are significant medical problems that ensue from activation of the innate immune system, significantly through chemokine receptors on microglia and neurons. Our latest advances deliver oral receptor-active peptides (RAPs) that potently and safely block select chemokine receptors including CCR2, CCR5, and CCR8 to treat chronic pain. Blocking CCR5 promotes memory and learning and reverses neurodegeneration in brain injuries . We identified natural chemokine antagonist peptides from the virobiome and turned them into candidate therapeutics. Their value is that “nature” has perfectly designed them to block innate immune viral defenses, but we can exploit those activities to normalize key inflammatory pathways that cause neuropathic pain and neurodegeneration. By shifting the bodies innate immune balance away from inflammation towards repair and regeneration our peptides have unique neuroregenerative actions to deliver benefits in stroke and traumatic brain injuries, or Alzheimer’s Disease, other dementias. Emerging evidence is also illuminating an exciting further use of our chemokine antgonist peptides in treating opioid and other substance abuse disorders.
Over 60 peer-reviewed pre-clinical and clinical publications on the 2nd generation, non-oral (nasal spray) peptide T, also called “DAPTA“, showed significant benefits in restoring synapses and preventing loss of cortical neurons via control of innate immune mechanisms. Multiple human trials showed normalized brain scans and improved cognitive function after several months treatment, especially in the more impaired patients. CCR5 is an emerging therapeutic target which our chemokine receptor antagonist peptides block. Next generation oral peptides, like RAP-103, with improved brain delivery are our current focus. Our lead uses are neuropathic pain, less opiate need in pain, dementia, brain injury, and stroke.